Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · IEX Real-Time Price · USD
10.64
-1.02 (-8.75%)
Sep 30, 2022 4:00 PM EDT - Market closed
-8.75%
Market Cap 1.84B
Revenue (ttm) 18.07M
Net Income (ttm) -233.90M
Shares Out 173.08M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000,465
Open 10.70
Previous Close 11.66
Day's Range 10.60 - 11.22
52-Week Range 4.92 - 23.39
Beta n/a
Analysts Buy
Price Target 17.54 (+64.8%)
Earnings Date Nov 8, 2022

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis... [Read more...]

Industry Biotechnology
IPO Date Apr 16, 2021
Employees 400
Stock Exchange NASDAQ
Ticker Symbol RXRX
Full Company Profile

Financial Performance

In 2021, RXRX's revenue was $10.18 million, an increase of 156.89% compared to the previous year's $3.96 million. Losses were -$186.48 million, 114.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is 17.54, which is an increase of 64.85% from the latest price.

Price Target
$17.54
(64.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of Clostridium...

2 weeks ago - PRNewsWire

These 3 Stocks Are the Future of Biotechnology

Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.

Other symbols: RGENVRTX
4 weeks ago - The Motley Fool

Recursion to Participate in Upcoming Investor Conferences

SALT LAKE CITY , Sept. 1, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in...

1 month ago - PRNewsWire

Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

SALT LAKE CITY , Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently rec...

1 month ago - PRNewsWire

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.57% and 37.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results

Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomas On track to initiate our Phase 2 clinical trial for the potential treat...

1 month ago - PRNewsWire

Recursion to Participate in Upcoming Investor Conference

SALT LAKE CITY , Aug. 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in ...

2 months ago - PRNewsWire

Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Poly...

SALT LAKE CITY , July 21, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Co...

2 months ago - PRNewsWire

3 Amazing Stocks Under $10

Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.

Other symbols: AGENSPNE
2 months ago - The Motley Fool

Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Fo...

If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been granted F...

3 months ago - PRNewsWire

3 Cathie Wood Stocks That Could Deliver Monster Returns

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Other symbols: BEAMTXG
3 months ago - The Motley Fool

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results

Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive NF2-mutated...

4 months ago - PRNewsWire

Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

SALT LAKE CITY , April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food ...

5 months ago - PRNewsWire

Recursion Publishes First Environmental, Social and Governance (ESG) Report

Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on net-zero gree...

6 months ago - PRNewsWire

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel pot...

6 months ago - PRNewsWire

Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease ...

6 months ago - PRNewsWire

Recursion Provides Updated Guidance on Clinical Trial Starts

SALT LAKE CITY , March 3, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts: Recursion's leadership team has decided that conducting a dose optimizat...

6 months ago - PRNewsWire

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing N...

SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development a...

9 months ago - PRNewsWire

Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities

SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ --  Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development ...

9 months ago - PRNewsWire

Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments

SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ --  Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development...

10 months ago - PRNewsWire

Why Recursion Pharmaceuticals Stock Sank Today

Investors reacted negatively to the company's Q3 update.

10 months ago - The Motley Fool

Recursion Provides Business Updates and Reports Third Quarter 2021 Financials

SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- Recursion (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, autom...

10 months ago - PRNewsWire

Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas

SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automat...

11 months ago - PRNewsWire

BioHive Names Katelin Roberts Executive Director

SALT LAKE CITY--(BUSINESS WIRE)--BioHive, with a mission to brand, build and bring together Utah's robust and growing life sciences industry, names Katelin Roberts Executive Director.

11 months ago - Business Wire